OLYSIO TM
(simeprevir) has been approved by the FDA in late 2013 and is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) mas Olysio
(simeprevir) has been approved by the FDA in late 2013 and is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) mas Olysio